



mylife CamAPS FX app

mylife CamAPS FX is an automated insulin delivery system that automatically adjusts insulin delivery on your mylife YpsoPump insulin pump, based on your sensor glucose readings.

- **Available for all age groups**

The mylife CamAPS FX app is approved for people with type 1 diabetes aged one year and over, including pregnant women. Approved for people with type 1 diabetes aged two years and over when used in combination with Dexcom G6 or FreeStyle Libre 3 Plus.

- **Self-learning**

Learning from previous insulin delivery and meal bolus information to adapt to diurnal, day-to-day as well as post-meal insulin needs.

- **Adaptive and personalised to you**

- Predictive control (the algorithm calculates the insulin requirement for the next 2.5–4 hours) and adaptive model (insulin delivery is adjusted every 8–12 minutes based on CGM data received every minute with FreeStyle Libre 3 Plus or every 5 minutes with Dexcom G6).
- Customisable personal glucose target in 30 minute segments across the 24 hours of the day in a range from 4.4–11.0mmol/L (80–198 mg/dL).

- **Runs on your smartphone**

Compatible with the Android OS. iOS will follow. Utilises Bluetooth connectivity to deliver automated insulin delivery. Internet connectivity is required to upload data to Glooko®, Companion and generate PDF reports.

- **Choice of CGM**

The mylife CamAPS FX system is compatible with Dexcom G6 or Abbott FreeStyle Libre 3 Plus Continuous Glucose Monitoring (CGM) System.

- **Insulin compatibility**

You can use any rapid or ultra-rapid acting insulin compatible with the mylife YpsoPump insulin pump (consult the mylife YpsoPump Instructions for Use).

- **Smartphone-based approach**

The app-based approach of diabetes management on a smartphone allows for an ongoing and more flexible development and improvement of the system thanks to free and regular mylife CamAPS FX app updates.

- **“Ease off” mode**

Can be used when less insulin is required, for example during physical activity.

- **“Boost” mode**

Can be used when more insulin is required, for example in case of one-off post-meal high glucose, when sick or during pre-menstrual period.

- **“Slowly absorbed meal” function**

With the “Slowly absorbed meal” function the algorithm will deliver extra insulin over 3–4 hours to cover the impact of a higher fat, higher protein or lower glycaemic index (GI) meal, depending on your glucose levels.



■ Remote monitoring

- Companion remote monitoring: the mylife CamAPS FX app allows user's data to be shared with up to 10 "companions". Remote monitoring is integrated into the app and therefore both, user and "companion", use the mylife CamAPS FX app. Companion remote monitoring mirrors the data from the user's mylife CamAPS FX app. Data is updated every minute (CGM data, insulin data, alerts) or every 5 minutes (other data) in the "companion's" mylife CamAPS FX app. Internet connectivity is required to share data with "companions".
- SMS based remote monitoring: the mylife CamAPS FX app supports SMS based remote monitoring. All mylife CamAPS FX app-generated alarms and alerts will be sent via SMS message to up to 5 "followers". Users must have a SIM-Card to allow SMS to be sent from their phone. We advise users to check their mobile plan includes SMS coverage.
- Both, Companion and SMS remote monitoring function, can be made inactive when they are not needed in the share menu of the child's / young adult's mylife CamAPS FX app.

■ PDF report function

Generation and export of PDF reports including glucose statistics, insulin statistics, "Auto mode" and alert statistics, information about settings and weekly overviews directly from the mylife CamAPS FX app. Internet connectivity and consent to share data are required to generate PDF reports.

■ Comprehensively tested

Developed at the University of Cambridge over more than a decade. Randomised clinical trials published in leading medical journals have shown a consistent improvement in glycaemic control as well as quality of life.



The Cambridge control algorithm has been tested in more than 15 clinical trials involving over 300 participants.


Runs on Android phones.
iOS will follow.





The CamDiab journey

A timeline of how the team behind mylife CamAPS FX came to help those with type 1 diabetes with the Cambridge algorithm.



mylife CamAPS FX is compatible with:

- mylife YpsoPump insulin pump
- Dexcom G6 or Abbott FreeStyle Libre 3 Plus Continuous Glucose Monitoring (CGM) System
- Android smartphones compatible with Dexcom: www.dexcom.com/compatibility
- Android smartphones compatible with FreeStyle Libre 3 Plus: www.diabetescare.abbott/support/manuals (see document “Mobile Device & OS Compatibility”). If using a FreeStyle Libre 3 Plus Sensor, please ensure you have an Android smart device with NFC (near field communication).
- For Companion remote monitoring only: Android smartphones running OS 8 and above.
- Glooko (for data sharing with your clinic)

rtCGM: real time continuous glucose monitoring

mylife YpsoPump and CamAPS FX are class IIb devices. Only rapid-acting insulin at a concentration of 100 U/ml (insulin analogue) may be used with the mylife YpsoPump system. Always read the label and use only as directed. Consult your healthcare professional to see if these products are right for you.

Disclaimer: The product images are for illustrative purposes only. // mylife and YpsoPump are registered trademarks of Ypsomed AG. // CamAPS is a registered trademark of CamDiab Ltd. // Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. in the United States and/or other countries. // The sensor housing, FreeStyle, Libre and related brand marks are marks of Abbott. // The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks by Ypsomed is under license. // Other trademarks and trade names are those of their respective owners. // **mylife Loop with FreeStyle Libre 3 Plus: The innovation described is available in selected countries and expanding to further countries soon. Expansion is contingent upon local regulatory approval**

For safety information on mentioned products, see Instructions for Use.